Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
January 4th 2016

Improving Precision and Outcomes of Cancer Surgery

Surabhi Dangi-Garimella, PhD
An imaging agent that can eliminate the unknown and help instill confidence in a surgeon’s ability to successfully remove all cancerous tissue is being evaluated by surgical oncologists at Duke University.
Site Logo
January 3rd 2016

Age Affects Breast Cancer Patients' Reaction to 2 Drugs

Jackie Syrop
How well postmenopausal patients tolerate tamoxifen and anastrozole for one type of breast cancer varies with age.
Site Logo
January 2nd 2016

Older Women with Breast Cancer Survive Better with Treatment Therapy

Priyam Vora
Women over 65 years of age with early-stage, fast-spreading breast cancer had better chances of surviving if they endured treatment therapy, according to a new study.
Site Logo
January 1st 2016

5 Things to Know About Biosimilars in the New Year

Surabhi Dangi-Garimella, PhD
An update on where the field of biosimilars currently stands.
Site Logo
December 31st 2015

Can Virtual Colonoscopies Be a Reality for Population Screening?

Surabhi Dangi-Garimella, PhD
A study published in the Journal of the National Cancer Institute found that ease of preparation prior to the screening test is an important determinant of colonoscopy uptake.
Site Logo
December 31st 2015

Aspirin May Lower Breast Tissue Density, Lead to Early Detection of Cancer

Jackie Syrop
New data does not support the idea that aspirin has protective qualities and “down-the-road” benefits for breast cancer patients. It may, however, help reduce breast density and improve earlier detection of some breast cancers.
Closing Statements
December 30th 2015

Closing Statements

Are Patients Aware of Site of Care Differentials?
December 30th 2015

Are Patients Aware of Site of Care Differentials?

Disparity in Site of Care Costs and Patient Burden
December 30th 2015

Disparity in Site of Care Costs and Patient Burden

The Path to Site Neutrality
December 30th 2015

The Path to Site Neutrality

Performance-Based Contracting in Oncology
December 30th 2015

Performance-Based Contracting in Oncology

Can Indication-Based Pricing Be a Reality?
December 30th 2015

Can Indication-Based Pricing Be a Reality?

Oral Parity Laws and Patient Cost Sharing
December 30th 2015

Oral Parity Laws and Patient Cost Sharing

Drug Prices and Patient Burden in Oncology
December 30th 2015

Drug Prices and Patient Burden in Oncology

Bundled Payments in Oncology: What Do Payers Think?
December 30th 2015

Bundled Payments in Oncology: What Do Payers Think?

Implications of Bundled Payments in Oncology
December 30th 2015

Implications of Bundled Payments in Oncology

What Are the Constructs of Value-Based Care?
December 30th 2015

What Are the Constructs of Value-Based Care?

Can Academic Innovation in LDTs Be Halted?
December 30th 2015

Can Academic Innovation in LDTs Be Halted?

LDTs and the Political Wheelhouse
December 30th 2015

LDTs and the Political Wheelhouse

Justifying the Need for FDA Regulation of LDTs
December 30th 2015

Justifying the Need for FDA Regulation of LDTs

Payer and Consumer Response to FDA Regulation of LDTs
December 30th 2015

Payer and Consumer Response to FDA Regulation of LDTs

What Are LDTs and How Are They Regulated?
December 30th 2015

What Are LDTs and How Are They Regulated?

Introduction
December 30th 2015

Introduction

Site Logo
December 30th 2015

Physicians Discover Palbociclib Effective in Cancers Beyond Those of the Breast

Surabhi Dangi-Garimella, PhD
A literature review by researchers at the Abramson Cancer Center has identified a potential use of the cell cycle inhibitor palbociclib in a variety of cancers.
Site Logo
December 30th 2015

Most-Read Articles From AJMC's Conference Coverage in 2015

Surabhi Dangi-Garimella, PhD
Studies that provided updates on new drug trials, sessions on value-based care, and the cost of healthcare, were most popular among readers of The American Journal of Managed Care.
Site Logo
December 29th 2015

Using Technology to Bring Palliative Care to the Patient's Doorstep

Surabhi Dangi-Garimella, PhD
After having launched a palliative care program in 2014, Cambia Health Solutions is now looking for ways to improve patient access to these tools that can improve a patient's quality of life.
Site Logo
December 29th 2015

Cost, Value of Cancer Drugs Take Center Stage in Current Issue of AJMC's Evidence-Based Oncology

One of the biggest stories of 2015 has been the cost of cancer drugs, which create vexing questions for payers and policymakers, as well as doctors and families. The tough choices being made today are the theme of the latest special issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.
Site Logo
December 28th 2015

Improving Cancer Trial Participation via Web-Based Interventions

Surabhi Dangi-Garimella, PhD
Patient awareness and educational support can improve their attitude as well as prepare them to make better informed decisions on clinical trial participation, a new study has found.
Site Logo
December 28th 2015

Report: Shkreli Arrest Prompts Cancer Center to Stop Trial

Mary K. Caffrey
Moffitt Cancer Center said there's nothing wrong with the drug, but a spokesman said the trial is halted for now pending the outcome of the investigation.
Site Logo
December 28th 2015

Cancer's Toll Beyond the Disease: Medical Costs and Productivity

Surabhi Dangi-Garimella, PhD
A new study published by the American Cancer Society found that younger colorectal cancer survivors end up spending over $8500 annually in medical expenses and they also experience significantly greater loss of productivity compared with individuals without cancer.
<1
...
113114115116117118119120121
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo